Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer

HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- or ER-targeting agents can lead to the acquisition of therapeutic resistance due to compensatory receptor crosstalk. New drug combinations targeting HER2 and ER could improve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2025-01, Vol.26 (2), p.460
Hauptverfasser:	Mahdi, Amira F, Ashfield, Niall, Crown, John, Collins, Denis M
Format:	Artikel
Sprache:	eng
Schlagworte:	Ado-Trastuzumab Emtansine - pharmacology Ado-Trastuzumab Emtansine - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis - drug effects Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell growth Cell Line, Tumor Cell Proliferation - drug effects Drug Resistance, Neoplasm - drug effects Drug Synergism Endocrine therapy Female Humans Kinases Lapatinib - pharmacology Lapatinib - therapeutic use Ligands Lymphocytes Oxazoles Protein Kinase Inhibitors - pharmacology Proteins Pyridines Quinazolines - pharmacology Quinazolines - therapeutic use Quinolines - pharmacology Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Trastuzumab - pharmacology Trastuzumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!